nach oben

Erschienen in:

01.05.2012 | Original Article

Validity of the Oxford classification of IgA nephropathy in children

verfasst von: Yuko Shima, Koichi Nakanishi, Taketsugu Hama, Hironobu Mukaiyama, Hiroko Togawa, Yuya Hashimura, Hiroshi Kaito, Mayumi Sako, Kazumoto Iijima, Norishige Yoshikawa

Erschienen in: Pediatric Nephrology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

In 2009, the Oxford classification of IgA nephropathy was published. However, its validity has not been fully examined in children. This study aimed to assess this system in an independent large-scale cohort of children.

Methods

We analyzed 161 consecutive children with newly diagnosed IgA nephropathy from 1977 to 1989 retrospectively. We examined the ability of each variable in the Oxford classification as a predictor of renal outcome defined as ≥ stage III chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m²) using Cox regression analysis.

Results

The mean mesangial score, and ratios of segmental glomerulosclerosis, endocapillary hypercellularity, tubular atrophy, and crescents were 0.49, 0.8%, 13.1%, 3.3%, and 9.2% respectively. Seven cases reached ≥ stage III CKD. In univariate analyses, mesangial hypercellularity score, endocapillary hypercellularity, tubular atrophy, and crescents were significant predictors of renal outcome. In a multivariate analysis, only mesangial hypercellularity score, tubular atrophy, and crescents were significant though, depending on models. Segmental glomerulosclerosis was not a significant predictor of renal outcome. Although the significance of crescents was not addressed in the Oxford classification, crescents were important predictors of outcome.

Conclusions

The Oxford classification appears to be valid for predicting renal outcome in children.

Donadio JV, Grande JP (2002) IgA nephropathy. N Engl J Med 347:738–748PubMedCrossRef

Alexopoulos E (2004) Treatment of primary IgA nephropathy. Kidney Int 65:341–355PubMedCrossRef

Appel GB, Waldman M (2006) The IgA nephropathy treatment dilemma. Kidney Int 69:1939–1944PubMedCrossRef

Yoshikawa N, Tanaka R, Iijima K (2001) Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol 16:446–457PubMedCrossRef

Yoshikawa N, Ito H, Nakamura H (1992) Prognostic indicators in childhood IgA nephropathy. Nephron 60:60–67PubMedCrossRef

Barratt J, Feehally J (2006) Treatment of IgA nephropathy. Kidney Int 69:1934–1938PubMedCrossRef

Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545PubMedCrossRef

Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D’Agati V, D’Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76:546–556PubMedCrossRef

Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2010) The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 77:921–927PubMedCrossRef

10.

Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N (2008) Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol 23:905–912PubMedCrossRef

11.

Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, Hataya H, Honda M, Iijima K, Yoshikawa N, for the Japanese Pediatric IgA Nephropathy Treatment Study Group (2011) Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol 6:1301–1307PubMedCrossRef

12.

Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, Honda M, Yoshikawa N, The Japanese Pediatric IgA Nephropathy Treatment Study Group (2009) Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol 24:845–849PubMedCrossRef

13.

Yoshikawa N, Ito H (1999) Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy—is it relevant for adult patients? Nephrol Dial Transplant 14:1097–1099PubMedCrossRef

14.

Japanese Pediatric IgA Nephropathy Treatment Group (1999) A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 10:101–109

15.

Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H (2006) Steroid treatment for severe childhood IgA nephropathy: a randomized controlled trial. Clin J Am Soc Nephrol 1:511–517PubMedCrossRef

16.

Yoshikawa N, Nakanishi K, Ishikura K, Hataya H, Iijima K, Honda M, Japanese Pediatric IgA Nephropathy Treatment Study Group (2008) Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol 23:757–763PubMedCrossRef

17.

Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMed

18.

Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS; National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (2003) National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 111:1416–1421PubMedCrossRef

19.

Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, Hunley TE, Hladunewich MA, Julian BA, Fervenza FC, Cattran DC (2011) Validation of the Oxford classification of IgA nephropathy. Kidney Int 80:310–317PubMedCrossRef

20.

Edström Halling S, Söderberg MP, Berg UB (2011) Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant. doi:10.1093/ndt/gfr339 PubMed

Titel: Validity of the Oxford classification of IgA nephropathy in children
verfasst von: Yuko Shima
Koichi Nakanishi
Taketsugu Hama
Hironobu Mukaiyama
Hiroko Togawa
Yuya Hashimura
Hiroshi Kaito
Mayumi Sako
Kazumoto Iijima
Norishige Yoshikawa
Publikationsdatum: 01.05.2012
Verlag: Springer-Verlag
Erschienen in: Pediatric Nephrology / Ausgabe 5/2012
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-011-2061-0

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Validity of the Oxford classification of IgA nephropathy in children